Mediastinal bulky tumour in Hodgkin's disease and prognostic value of positron emission tomography in the evaluation of post-treatment residual masses

Acta Haematologica

Volumn 112, Issue 4, 2004, Pages 194-199

  Keresztes, Katalin ^a   Lengyel, Zsolt ^a   Devenyi, Katalin ^a   Vadasz, Györgyi ^a   Miltenyi, Zsofia ^a   Illes, Arpad ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Hodgkin's disease; Mediastinal neoplasms; Positron emission tomography

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; LOMUSTINE; PREDNIMUSTINE; PREDNISOLONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM TUMOR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RADIODIAGNOSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR VOLUME;

CHILD; CHILD, PRESCHOOL; DIAGNOSTIC ERRORS; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; INFANT; MALE; NEOPLASM, RESIDUAL; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 9144226489     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081271     Document Type: Article

References (28)

1. Amini RM, Glimelius B, Gustavsson A, Ekman T, Erlanson M, Haapaniemi E, Enblad G: A population-based study of the outcome for patients with first relapse of Hodgkin's lymphoma. Eur J Haematol 2002;68:225-232.
2. Chronowski GM, Wilder RB, Tucker SL, Ha CS, Sarris AH, Hagemeister FB, Barista I, Hess MA, Cabanillas F, Cox JD: An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease. Cancer 2002;95:2534-2538.
3. Longo DL, Glatstein E, Duffey PL, Young RC, Ihde DC, Bastian AW, Wilson WH, Wittes RE, Jaffe ES, Hubbard SM, DeVita VT Jr: Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease. J Clin Oncol 1997;15:3338-3346.
4. Bonadonna G, Valagussa P, Santoro A: Prognosis of bulky Hodgkin's disease treated with chemotherapy alone or combined with radiotherapy. Cancer Surv 1985;4:439-445.
5. Cosset JM, Henry-Amar M, Carde P, Clarke D, Le Bourgeois JP, Tubiana M: The prognostic significance of large mediastinal masses in the treatment of Hodgkin's disease. The experience of the Institute Gustave-Roussy. Hematol Oncol 1984;2:33-43.
6. Aviles A, Delgado S: A prospective clinical trial comparing chemotherapy, radiotherapy and combined therapy in the treatment of early stage Hodgkin's disease with bulky disease. Clin Lab Haematol 1998;20:95-99.
7. Aviles A, Delgado S, Talavera A, Gonzalez JL, Diaz Maqueo JC: Malignancy: Adjuvant radiotherapy to initial bulky disease in patients with advanced stage Hodgkin's disease. Hematology 2000;4:479-485.
8. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, Rosenberg SA, Coltman CA, Tubiana M: Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7:1630-1636.
9. Schulte M, Brecht-Krauss D, Heymer B, Guhlmann A, Hartwig E, Sarkar MR, Diederichs CG, Schulteiss M, Kotzerke J, Reske SN: Fluorodeoxyglucose positron emission tomography of soft tissue tumours: Is a non-invasive determination of biological activity possible? Eur J Nucl Med 1999;26:599-605.
10. Mauch P, Goodman R, Hellman S: The significance of mediastinal involvement of early stage Hodgkin's disease. Cancer 1978;42:1039-1045.
11. Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA: Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: Mature results of a prospective clinical trial. J Clin Oncol 2002;20:630-637.
12. Naumann R, Vaic A, Beuthien-Baumann B, Bredow J, Kropp J, Kittner T, Franke WG, Ehninger G: Prognostic value of positron emission tomography in the evaluation of posttreatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 2001;115:793-800.
13. Garcia-Carbonero R, Paz-Ares L, Arcedino A, Lahuerta J, Bartolome A, Cortes-Funes H: Favorable prognosis after late relapse of Hodgkin's disease. Cancer 1998;83:560-565.
14. Mauch P, Gorsshein D, Cunningham J: Influence of mediastinal adenopathy on site and frequency of relapse in patients with Hodgkin's disease. Cancer Treat Rep 1982;66:809-817.
15. Longo DL, Russo A, Duffey PL, Hubbard SM, Glatstein E, Hill JB, Jaffe ES, Young RC, DeVita VT Jr: Treatment of advanced-stage massive mediastinal Hodgkin's disease: The case for combined modality treatment. J Clin Oncol 1991;9:227-235.
16. Behar RA, Hoppe RT: Radiation therapy in the management of bulky mediastinal Hodgkin's disease. Cancer 1990;66:75-79.
17. Zinzani PL, Mazza P, Gherlinzoni F, Bocchia M, Fiacchini M, Bendandi M, Barbieri E, Frezza G, Neri S, Aitini E: Massive mediastinal involvement in stage I-II Hodgkin's disease: Response to combined modality treatment. Leuk Lymphoma 1992;8:81-85.
18. Hoppe RT, Coleman CN, Cox RS, Rosenberg SA, Kaplan HS: The management of stage I-II Hodgkin's disease with irradiation alone or combined modality therapy: The Stanford experience. Blood 1982;59:455-465.
19. Elconin JH, Roberts KB, Rizzieri DA, Vermont C, Clough RW, King C, Dodge RK, Prosnitz LR: Radiation dose selection in Hodgkin's disease patients with large mediastinal adenopathy treated with combined modality therapy. Int J Radiat Oncol Biol Phys 2000;48:1097-1105.
20. Zinzani PL, Magagnoli M, Frezza G, Barbieri E, Gherlinzoni F, Galuppi A, Bendandi M, Merla E, Albertini P, Babini L, Tura S: ABVD and radiation therapy as first-line treatment in advanced Hodgkin's disease. Leuk Lymphoma 1999;32:553-559.
21. Canellos GP, Gollub J, Neuberg D, Mauch P, Shulman LN: Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year followup. Ann Oncol 2003;14:268-272.
22. Horning SJ, Williams J, Bartlett NL, Bennett JM, Hoppe RT, Neuberg D, Casselith P: Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492. J Clin Oncol 2000;18:972-980.
23. Hoppe RT: Radiation therapy in the treatment of Hodgkin's disease. Semin Oncol 1980;7:144-154.
24. Mazza P, Lauria F, Sciascia R, Emiliani E, Fiacchini M, Baccarani M, Frezza G, Dominici G, Cantore M, Faedi M: Prognostic significance of large mediastinal involvement in Hodgkin's disease. Scand J Haematol 1983;31:315-321.
25. Gossot D, Girard P, de Kerviler E, Brice P, Rain JD, Leblanc T, Grunenwald D: Thoracoscopy or CT-guided biopsy for residual intrathoracic masses after treatment of lymphoma. Chest 2001;120:289-294.
26. 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001;98:2930-2934.
27. Sandherr M, von Schilling C, Link T, Stock K, von Bubnoff N, Peschel C, Avril N: Pitfalls in imaging Hodgkin's disease with computed tomography and positron emission tomography using fluorine-18-fluorodeoxyglucose. Ann Oncol 2001;12:719-722.
28. Zhuang H, Yamamoto AJ, Sinha P, Pourdehnad M, Liu Y, Alavi A: Similar pelvic abnormalities on FDG positron emission tomography of different origins. Clin Nucl Med 2001;26:515-517.